1. < Neuroendocrine Tumors (NETs)

Metastasis to the Liver Caudate Region (Segment 1)

Posted by markmark007 @markmark007, 1 day ago

In reference to my wife:
Recent C/T of abdomen and pelvis showed "increased hypervascularity in the haptic metastasis in the caudate". Initial discovery
Background:
NET cancer confirmed in 2014 - primary was pancreas - metastasis to liver, bones confirmed in 2017.
She has had 4 regiments of PRRT (completed July 2023); monthly injections of octreotide since completion of PRRT; monthly lanreotide injections pre - PRRT
Questions:
1. Can anyone with caudate lesions comment on their experiences?
2. Has anyone used histotripsy for treatment? (side note: is available where we live - will contact Swedish)
Any comments will be sincerely appreciated -
Thanks,
Mark

Interested in more discussions like this? Go to the Neuroendocrine Tumors (NETs) Support Group.

mcharlesfrancis | @mcharlesfrancis | 18 hours ago

The two prominent places for historic in the United States are at the University of Michigan or it was first studied and in Mission Viejo, California

REPLY
1 reply
mcharlesfrancis | @mcharlesfrancis | 18 hours ago

University of Michigan Roger Cancer Center is probably the most experienced site in histotripsy that was approved by the FDA since late 2023 for non-invasive ablation of liver tumors, including metastasis from pancreatic cancer. It requires patients have oligometastatic disease and that is no more than 5 tumors up to a size of 5 cm.

There are two key MD’s involved with the development of the procedure, clinical trial and studies. They are Clifford Cho, MD and Mishal Mendiratta-Lala, MD. One’s oncologist is best to make contact with either of these two physicians. Have the oncologist submit a referral to the Rogel Cancer Center via their Cancer AnswerLine or if an oncologist is calling, look on the aRogel,Cancer site for M-Line contact info.

Next request a multidisciplinary liver tumor clinic. This likely can be done virtually with the requestor. Mention histotripsy specifically for pancreatic metastatic disease. The requestor should specifically request coordination with Drs. Cho, Mendiratta-Layla and Dr.Xu who is one of the PhD developers of the technology.. This will likely get consideration for advanced options.

Phone for patients: 800-865-1125
E-Mail: CancerAnswerLine@med.umich.edu
Hours: Mon—Fri, 8 am- 4:30 pm ET

REPLY
1 reply
markmark007 | @markmark007 | 18 hours ago
In reply to @mcharlesfrancis "The two prominent places for historic in the United States are at the University of Michigan..." + (show)
@mcharlesfrancis

The two prominent places for historic in the United States are at the University of Michigan or it was first studied and in Mission Viejo, California

Jump to this post

Sorry - I do not understand your response to my posting -
Mark

REPLY
markmark007 | @markmark007 | 17 hours ago
In reply to @mcharlesfrancis "University of Michigan Roger Cancer Center is probably the most experienced site in histotripsy that was..." + (show)
@mcharlesfrancis

University of Michigan Roger Cancer Center is probably the most experienced site in histotripsy that was approved by the FDA since late 2023 for non-invasive ablation of liver tumors, including metastasis from pancreatic cancer. It requires patients have oligometastatic disease and that is no more than 5 tumors up to a size of 5 cm.

There are two key MD’s involved with the development of the procedure, clinical trial and studies. They are Clifford Cho, MD and Mishal Mendiratta-Lala, MD. One’s oncologist is best to make contact with either of these two physicians. Have the oncologist submit a referral to the Rogel Cancer Center via their Cancer AnswerLine or if an oncologist is calling, look on the aRogel,Cancer site for M-Line contact info.

Next request a multidisciplinary liver tumor clinic. This likely can be done virtually with the requestor. Mention histotripsy specifically for pancreatic metastatic disease. The requestor should specifically request coordination with Drs. Cho, Mendiratta-Layla and Dr.Xu who is one of the PhD developers of the technology.. This will likely get consideration for advanced options.

Phone for patients: 800-865-1125
E-Mail: CancerAnswerLine@med.umich.edu
Hours: Mon—Fri, 8 am- 4:30 pm ET

Jump to this post

Many thanks !!

Mark

REPLY
markmark007 | @markmark007 | 17 hours ago
In reply to @mcharlesfrancis "Histotripsy" + (show)
@mcharlesfrancis

Histotripsy

Jump to this post

Sorry I do not understand your response to the questions I posted.
Mark

REPLY
Please sign in or register to post a reply.